Roche has a series of immunoassays that can be run on the Cobas in vitro diagnostic analysers developed in collaboration with Hitachi High-Tech. Image Credit: JHVEPhoto / Shutterstock.

Roche and Hitachi High-Tech have signed a ten-year contract renewal to jointly develop and manufacture diagnostic solutions.

The agreement follows a successful 46-year partnership that has yielded several analysers, including Cobas analysers used to run various in vitro diagnostic assays.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The companies plan to launch new analytical units, namely cobas c 703 and cobas ISE neo; as well as a fully automated mass spectrometry integration, cobas Mass Spec solution, by the end of this year.

The in vitro diagnostics market was worth approximately $49.6bn last year, according to GlobalData analysis. The in vitro diagnostic analyser sub-section of the market was worth approximately $4.8bn last year and is expected to generate over $7.8bn in sales by 2033.

“I am delighted that with this new agreement, Roche and Hitachi High-Tech can continue to push the boundaries of medical technology and transform patient care,” commented Palani Kumaresan, head of Roche Diagnostic Solutions.

See Also:

“Together, we have built an unrivalled installed base of more than 84,000 diagnostic platforms around the globe. This brings both speed and scale to testing for our customers, helping them to better serve patients’ needs.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roche has expanded its portfolio of molecular assays, which are run on cobas systems, with multiple approvals from the US Food and Drug Administration (FDA) in recent months. In March, the company received US approval for the first-ever blood screening test for malaria. The test is run on the polymerase chain reaction (PCR)-based cobas 6800/8800 systems and allows healthcare professionals to screen for the disease in blood, organ, and tissue donors.

Roche’s blood test portfolio includes multiple immunoassays such as Elecsys HBeAg quant to diagnose and monitor hepatitis B, Anti-HEV IgM and Elecsys Anti-HEV IgG immunoassays for detecting hepatitis E virus (HEV) infections, neurofilament light chain (NfL) test for diagnosing multiple sclerosis and interleukin 6 (IL-6) immunoassay for diagnosing neonatal sepsis. The tests are run on different cobas e analysers.